EA Perez

795 total citations
32 papers, 617 citations indexed

About

EA Perez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, EA Perez has authored 32 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in EA Perez's work include HER2/EGFR in Cancer Research (15 papers), Cancer Treatment and Pharmacology (11 papers) and Advanced Breast Cancer Therapies (9 papers). EA Perez is often cited by papers focused on HER2/EGFR in Cancer Research (15 papers), Cancer Treatment and Pharmacology (11 papers) and Advanced Breast Cancer Therapies (9 papers). EA Perez collaborates with scholars based in United States, Belgium and Italy. EA Perez's co-authors include VJ Suman, N E Davidson, Robert B. Jenkins, Brittany L. Murphy, P. Kaufman, Patrick C. Roche, J. N. Ingle, Silvana Martino, Cristina Oliva and Judit Kocsis and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

EA Perez

32 papers receiving 587 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
EA Perez United States	11	541	279	172	162	102	32	617
Mary-Ann Lindsay United States	5	487 0.9×	203 0.7×	182 1.1×	162 1.0×	151 1.5×	5	588
Roberta Guzman United States	8	539 1.0×	289 1.0×	248 1.4×	235 1.5×	107 1.0×	11	684
Angela Santiago United States	7	516 1.0×	289 1.0×	216 1.3×	230 1.4×	115 1.1×	9	665
Ivonne Villalobos United States	10	681 1.3×	398 1.4×	309 1.8×	296 1.8×	148 1.5×	13	863
N E Davidson United States	8	397 0.7×	204 0.7×	167 1.0×	289 1.8×	47 0.5×	10	660
Eleonora Nicolò Italy	12	496 0.9×	222 0.8×	149 0.9×	116 0.7×	179 1.8×	39	635
Isabelle Desmoulins France	15	361 0.7×	191 0.7×	271 1.6×	84 0.5×	205 2.0×	75	624
Merdol Ibrahim United Kingdom	15	469 0.9×	262 0.9×	275 1.6×	254 1.6×	146 1.4×	19	735
P. Gómez Pardo Spain	9	566 1.0×	159 0.6×	158 0.9×	91 0.6×	367 3.6×	27	716
Tanja Badovinac-Črnjević United States	7	418 0.8×	185 0.7×	120 0.7×	68 0.4×	161 1.6×	9	533

Countries citing papers authored by EA Perez

Since Specialization

Citations

This map shows the geographic impact of EA Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EA Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EA Perez more than expected).

Fields of papers citing papers by EA Perez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EA Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EA Perez. The network helps show where EA Perez may publish in the future.

Co-authorship network of co-authors of EA Perez

This figure shows the co-authorship network connecting the top 25 collaborators of EA Perez. A scholar is included among the top collaborators of EA Perez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EA Perez. EA Perez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharma, Monica, Richard D. Carvajal, Glenn J. Hanna, et al.. (2021). 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Annals of Oncology. 32. S1453–S1454. 6 indexed citations

Lin, NU, et al.. (2016). Abstract OT3-01-04: An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for the treatment of central nervous system progression post-radiotherapy in patients with HER2-positive metastatic breast cancer (PATRICIA). Cancer Research. 76(4_Supplement). OT3–1. 1 indexed citations

Perez, EA, Eileen Holmes, Evandro de Azambuja, et al.. (2014). Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc). Annals of Oncology. 25. v1–v1. 2 indexed citations

Adams, Sylvia, Sandra Demaria, LJ Goldstein, et al.. (2013). Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. Cancer Research. 73(24_Supplement). S1–7. 13 indexed citations

Perez, EA, et al.. (2012). Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study. Cancer Research. 72(24_Supplement). PD10–4. 4 indexed citations

Borgés, Sahra, et al.. (2012). Abstract P1-05-24: Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.. Cancer Research. 72(24_Supplement). P1–5. 6 indexed citations

Lembersky, BC, Louis Fehrenbacher, CI Falkson, et al.. (2011). S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.. Cancer Research. 71(24_Supplement). S2–3. 14 indexed citations

Bondarenko, Igor, John A. Glaspy, Adam Brufsky, et al.. (2010). 476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1. European Journal of Cancer Supplements. 8(3). 198–198. 1 indexed citations

Dell’Orto, Patrizia, RD Gelber, Luca Russo, et al.. (2010). Abstract P3-10-36: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708). Cancer Research. 70(24_Supplement). P3–10. 4 indexed citations

10.

Gray, Robert P., LJ Goldstein, BH Childs, et al.. (2009). GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer.. Cancer Research. 69(2_Supplement). 25–25. 3 indexed citations

11.

Perez, EA, et al.. (2009). Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic cancer research consortium trial RC0639.. Cancer Research. 69(2_Supplement). 2109–2109. 2 indexed citations

12.

Rowland, K. M., et al.. (2009). Meta-analysis of adverse event rates in 15 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials for the development of adverse event stopping rules.. Cancer Research. 69(2_Supplement). 6149–6149. 2 indexed citations

13.

Piccart-Gebhart, M.J., EA Perez, José Baselga, et al.. (2007). P118 ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 2-06/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer (BC). The Breast. 16. S46–S47. 20 indexed citations

14.

Ewer, Michael S., EA Perez, José Baselga, et al.. (2007). P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer. The Breast. 16. S63–S63. 21 indexed citations

15.

Perez, EA, et al.. (2006). Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study. European Journal of Cancer Supplements. 4(2). 113–113. 1 indexed citations

16.

Roche, Patrick C., VJ Suman, Robert B. Jenkins, et al.. (2002). Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831. JNCI Journal of the National Cancer Institute. 94(11). 855–857. 313 indexed citations

17.

Perez, EA. (2001). The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies. Current Oncology Reports. 3(6). 516–522. 17 indexed citations

18.

Bonner, James A., Jeff A. Sloan, Kendrith M. Rowland, et al.. (2000). Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.. PubMed. 6(2). 597–601. 36 indexed citations

19.

Perez, EA, Francois J. Geoffroy, Joel M. Reid, Henry D. Tazelaar, & Joseph P. Grill. (1997). 53 Phase II study and pharmacokinetics of oral etoposide and intravenous paclitaxel in extensive stage small cell lung cancer: An NCCTG study. Lung Cancer. 18. 17–17. 1 indexed citations

20.

Perez, EA. (1990). Estudio epidemiológico del suicidio: comparación de dos periodos (1931-1950 y 1961-1980). Psiquis: Revista de psiquiatría, psicología médica y psicosomática. 11(8). 31–37. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact